PARIS--(BUSINESS WIRE)--Regulatory News: AB Science SA (Paris:AB)(NYSE Euronext - FR0010557264 - AB), a pharmaceutical company specializing in the research, development and commercialization of protein kinase inhibitors (PKIs), announced today recruitment of the first patient in the phase 3 study of masitinib in the treatment of patients with relapsing multiple myeloma who received one previous therapy. Thanks to the recruitment of the 1st patient in this study, AB Science is now conducting 8 phase 3 studies.
